Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR-2), two protein tyrosine kinases, are involved in pathological disorders and the progression of different types of carcinomas. Concomitant inhibition of both tyrosine kinase activities appears to be an attractive target for cancer chemotherapy. A series of new quinazoline derivatives substituted by amide, urea, or carbamic acid ester groups have been synthesized. The biological activities of these new compounds have been evaluated for their enzyme inhibition and antiproliferative activities.
Garofalo
Antonio
A
Institut de Chimie Pharmaceutique Albert Lespagnol, Université Lille Nord de France, Lille, France.
Goossens
Laurence
L
Lemoine
Amelie
A
Farce
Amaury
A
Arlot
Yannick
Y
Depreux
Patrick
P
D000577:Amides / Q000737:chemistry; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D002219:Carbamates / Q000737:chemistry; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D011799:Quinazolines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D014508:Urea / Q000737:chemistry*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
D000577:Amides; D000970:Antineoplastic Agents; D002219:Carbamates; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D014508:Urea; D066246:ErbB Receptors; D040301:Vascular Endothelial Growth Factor Receptor-2; C070766:carbamic acid